Periodic fever syndromes, autoinflammatory diseases, Still’s disease and MAS/HLH
Karmela Kim Chan, MD
Hospital For Special Surgery
New York, NY, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Ami Shah, MD
Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine
Ellicott City, MD, United States
Disclosure(s): Arena Pharmaceuticals: Grant/Research Support (Ongoing); Eicos Sciences: Grant/Research Support (Terminated, January 29, 2023); Kadmon Corporation: Grant/Research Support (Ongoing); Medpace LLC: Grant/Research Support (Ongoing)
Immune checkpoint inhibitors are increasingly used to treat patients with cancer. These drugs, which activate T cells in hopes of promoting an anti-tumor immune response, can cause a variety of inflammatory side effects known as immune-related adverse events. Immune checkpoint inhibitors also commonly cause flares in patients with underlying autoimmune disease. The first part of the session will review immune-related adverse events most likely to be referred to rheumatology: inflammatory arthritis, polymyalgia rheumatica, and myositis. The second part of the session will focus on treatment of patients with preexisting autoimmune disease with immune checkpoint inhibitors.
Speaker: Ami Shah, MD – Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine
Speaker: Karmela Kim Chan, MD – Hospital For Special Surgery